Compare NetApp Inc. (NTAP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Tango Therapeutics Inc. — how do they compare? NetApp Inc. trades at $216 (market cap $46.95B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: NetApp Inc. is far larger — about 12.5× Tango Therapeutics Inc.'s market cap, and NetApp Inc. pays a 0.87% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| NTAP | TNGX | |
|---|---|---|
Market Cap | $46.95B | $3.75B |
Volume | 2,358,705 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $239.23 | $32.90 |
52-Week Low | $94.11 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $45.90B | $2.77B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $222.2, down 7.12% over the past day, yet maintains a strong fundamental profile with robust profitability margins and consistent earnings beats. The stock exhibits a bullish technical signal, supported by moving averages, though oscillators indicate potential overbought conditions. Recent strategic announcements at INSIGHT 2026, including AI infrastructure partnerships and new product launches, highlight the company's focus on capitalizing on data and AI-driven demand.
The outlook for NTAP is positive, driven by solid earnings growth, strategic AI initiatives, and favorable analyst sentiment, but risks include high valuation multiples, competitive pressures in the storage sector, and macroeconomic sensitivity. The consensus price target of $219.30 suggests limited near-term upside from current levels, warranting caution amid recent volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
